Second-line treatment options in hepatocellular carcinoma

Donatella Marino MD, Clizia Zichi MD, Marco Audisio MD, Elisa Sperti MD, Massimo Di Maio MD

Article Type

Review

Published

This review discusses the evidence on second-line options for hepatocellular carcinoma, focusing on the latest results that are currently refining the treatment scenario.

Read more

Efficacy of ruxolitinib retreatment in a patient with high-risk myelofibrosis using the international prognostic scoring system

Vincenzo Accurso MD, Marco Santoro MD, Salvatrice Mancuso MD, Marisante Napolitano MD, Florinda Di Piazza MD, Antonio Russo MD, Sergio Mario Siragusa MD

Article Type

Case Report

Published

This case report presents initial experience with a patient affected by primary myelofibrosis, retreated with ruxolitinib after a 3-month suspension of
therapy due to clinical decision.

Read more

Oral oncolytic and antiretroviral therapy administration: dose adjustments, drug interactions, and other considerations for clinical use

Melissa E Badowski PharmD, MPH, Bradley Burton PharmD, Kristy M Shaeer PharmD, MPH, John Dicristofano BS, PharmD Candidate

Article Type

Review

Published

This article evaluates existing literature through such means as drug databases and package inserts along with PubMed/Medline, Embase, and Google Scholar databases to develop a reference tool for providers to utilize when there is a decision to treat a patient with ART and oral oncolytic agents concurrently.

Read more

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.